Biomanufacturing refers to biotechnology that uses a biological system to produce biomaterial and biochemicals and use them in industrial application, food and beverage processing, and manufacturing using genetic engineering techniques. The next-generation biomanufacturing will be cost-effective as it incorporates various innovative technologies in a single facility in half the construction time and operating cost of medicines. The plant will have portable equipment and disposable components, which provides better agility and flexibility and speed in manufacturing.
The global next-generation biomanufacturing market to fuel the market growth at bolstering CAGR in the forecast period from 2020-2027 owing to rising technology in biomanufacturing products, increased funding by private investors and government, increasing environmental concerns, and the emerging need for seamless service in manufacturing.
Next-generation biomanufacturing will fuel the market demand for various industries like food and beverages, pharmaceuticals, and other industrial applications. Due to the rising need for utilization, the resources, improve waste management, cost-efficiency, and improves flexibility and speed of the medicines manufacturing leads to market growth.
Moreover, various start-ups with technical expertise are investing in next-generation biomanufacturing to overcome the shortcomings of existing biomanufacturing. Thus, promote the comprehensive upgrading of biomanufacturing and solve the ecological, resource, and sustainable development crisis.
Additionally, With the rapid development of molecular biology, biochemistry, and synthetic biology, industrial biotechnology that uses biological products such as living organisms, organelles, or enzymes to process raw materials in the form of biochemical reactions is considered to be a more effective means.
Furthermore, the rising adoption of single-use products, such as single-use bio-containers, and bioreactors have enhanced the market trends of the next-generation biomanufacturing market. As it promotes the green and clean environment, reduces contamination of the product, minimizes wastage and cost as well.
The next-generation biomanufacturing market will help to promote the seamless service, which enhances both the quality and efficiency of the product. Compared to the present generation biomanufacturing, next-generation manufacturing will fuel its market owing to the use of disposable products in the manufacturing plant to reduce waste and promote environmental benefits.
The technology advancement in biomanufacturing has the medicines quality and efficiency and reduce the construction time. The water and energy level have also reduced, which promotes low-level carbon emissions. Various technology advance manufacturing companies are using tools that help in understanding human biology and thus use human genetics tools to reduce the complexities of diseases.
Based on the workflow and product, the global next-generation biomanufacturing market segmented into Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing. Single-use upstream manufacturing has captured the largest segment in the global next-generation biomanufacturing market. Single-use upstream is further classified into Single-Use Bioreactors, Single-Use Bags and Containers, Single-Use Tubing and Connectors, Single-Use Mixing Systems, Single-Use Sensors, and Probes. The single-use bioreactors, bags, container, and other tools used in the manufacturing process as it helps in easy disposal, reduce the risk of contamination. It also reduces the cost associated with the sterilization, cleaning of the equipment and also optimizes the energy and minimizes the use of water. Therefore, the demand for next-generation biomanufacturing will capture the largest market share in the future.
Based on the Application, the global next-generation biomanufacturing market classified into Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, and Others. Recombinant proteins held the largest market share in the global next-generation biomanufacturing market—the recombinant proteins produced by applying recombinant DNA or recombinant RNA technology. The production of recombinant proteins in vitro mainly includes four significant systems: prokaryotic protein expression, mammalian cell protein expression, yeast protein expression, and insect cell protein expression. The E. coli expression system has become the most commonly used for recombinant protein production. Due to the high level of expression, low cost, simple culture conditions, rapid manufacturing, robust scalability, easy conversion, protein expression can optimize through multiple parameters, easy to form a disulfide bond.
Based on geography, the global next-generation biomanufacturing market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America will be expecting to witness the highest growth during the forecast period from 2020-2027. The rising disposable income, advancement in technology, people’s awareness of making the country pollution free and reduce carbon emission. It coupled with North America’s government initiatives in investing next-generation biomanufacturing. Thus, it will capture the most significant share the worldwide will fuel the demand for the global next-generation biomanufacturing demand.
Companies such as Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, bbi-biotech GmbH, Esco Group of Companies, Pierre Guérin, Solaris Biotechnology Srl., PBS Biotech, Inc., ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and Shanghai Bailun Biotechnology Co. Ltd among others are key players in the global next-generation biomanufacturing market.
|Market size value in 2020||USD 19.25 Billion|
|Revenue forecast in 2027||USD 40.3 Billion|
|Growth Rate||CAGR of 9.4% from 2020 to 2027|
|Forecast period||2021 – 2027|
|Region covered||North America, Europe, Asia-Pacific, South America, and Middle East & Africa|
|Key companies Profiled||Merck KGaA, Thermo Fisher Scientific Inc.,bbi-biotech GmbH, Esco Group of |
Companies, Pierre Guérin, Solaris Biotechnology Srl., Danaher Corporation,
Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, PBS Biotech, Inc.,
ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and
Shanghai Bailun Biotechnology Co. Ltd
By Work flow and Product
By Medical Application
Biomanufacturing produces biomaterial and biochemicals using biological systems in industrial applications, manufacturing, and food and beverage processing using genetic engineering techniques.
The calculated Next-Generation Biomanufacturing technology market value is USD 19.25 Billion in 2020 and will reach USD 40.3 Billion by 2027.
The growth rate of the Next Generation Biomanufacturing technology market is 9.4% during the forecast period.
Seamless service, Technological advancement are the driving forces of the Next Generation Biomanufacturing technology market.
By application, the Next Generation Biomanufacturing technology market is classified as Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others.